Galectin 9 and CXC-chemokine ligand 10 (CXCL10) have been validated as serum biomarkers of disease activity in a group of 125 patients with juvenile dermatomyositis (JDM) from three international cohorts. The combination of high concentrations of galectin 9 and CXCL10 was better able to differentiate patients with JDM with active disease from those in remission (area under curve (AUC) 0.86–0.90) than the standard marker creatine kinase (AUC 0.66–0.68), and could also predict flare several months before onset. Galectin 9 and CXCL10 were also predictive of active disease in adults with dermatomyositis.
References
Original article
Wienke, J. et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multi-cohort validation. Arthritis Rheumatol. https://doi.org/10.1002/art.40881 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Serum biomarkers of disease activity in JDM. Nat Rev Rheumatol 15, 250 (2019). https://doi.org/10.1038/s41584-019-0210-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0210-1